Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Steve Aselage Biography and Net Worth

Director of Travere Therapeutics

Mr. Aselage has been a member of the board of directors of Travere Therapeutics, Inc. since 2012. During his tenure as CEO of Travere from 2014 to January 2019, Mr. Aselage drew upon more than 30 years of biopharmaceutical experience to lead the transformation of the company. Following his appointment, Mr. Aselage solidified the company’s leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders. Prior to his appointment, Mr. Aselage was executive vice president and chief business officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi) and Bristol Laboratories. Mr. Aselage is also a member of the board of directors for Acer Therapeutics and BioCryst. Mr. Aselage received his B.S. in biology from the University of Notre Dame, and currently serves on the advisory council for the Department of Science at Notre Dame.

What is Steve Aselage's net worth?: The estimated net worth of Steve Aselage is at least $42,950.00 as of May 24th, 2024. Mr. Aselage owns 2,500 shares of Travere Therapeutics stock worth more than $42,950 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Aselage may own. Learn More about Steve Aselage's net worth.
How do I contact Steve Aselage?: The corporate mailing address for Mr. Aselage and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected]. Learn More on Steve Aselage's contact information.
Has Steve Aselage been buying or selling shares of Travere Therapeutics?: Steve Aselage has not been actively trading shares of Travere Therapeutics during the past quarter. Most recently, Steve Aselage sold 2,575 shares of the business's stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $21.92, for a transaction totalling $56,444.00. Following the completion of the sale, the director now directly owns 146,919 shares of the company's stock, valued at $3,220,464.48. Learn More on Steve Aselage's trading history.
Who are Travere Therapeutics' active insiders?: Travere Therapeutics' insider roster includes Steve Aselage (Director), Sandra Calvin (CAO), Laura Clague (CFO), Eric Dube (CEO), Peter Heerma (Insider), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?: During the last year, insiders at the sold shares 20 times. They sold a total of 172,896 shares worth more than $2,164,946.05. The most recent insider tranaction occured on November, 25th when CAO Sandra Calvin sold 12,090 shares worth more than $221,247.00. Insiders at Travere Therapeutics own 3.8% of the company. Learn More about insider trades at Travere Therapeutics.
Information on this page was last updated on 11/25/2024.

Steve Aselage Insider Trading History at Travere Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/11/2022	Sell	2,575	$21.92	$56,444.00	146,919
11/16/2021	Sell	31,800	$29.39	$934,602.00
11/5/2021	Sell	10,000	$26.23	$262,300.00
10/7/2021	Sell	60,000	$26.25	$1,575,000.00
4/16/2021	Sell	10,000	$26.23	$262,300.00	198,940
3/17/2021	Sell	17,727	$27.44	$486,428.88	206,667

Steve Aselage Buying and Selling Activity at Travere Therapeutics

Travere Therapeutics Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $17.18

$17.13

$17.88

50 Day Range

MA: $18.17

$16.86

$19.85

2 Week Range

Now: $17.18

$5.12

$20.33

Volume

3,699,463 shs

Average Volume

1,396,496 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.